Hepatobiliary manifestations following two-stages elective laparoscopic restorative proctocolectomy for patients with ulcerative colitis: A prospective observational study

Table 3 Factors affecting regression of hepatobiliary manifestations, n (%)

	Manifestations regression		P value
	Yes (n = 28)	No (n = 139)
Age (yr)	37 ± 7	36 ± 8	0.578
Sex
Males	21 (75)	91 (65.5)	0.327
Females	7 (25)	48 (34.5)
Smoking	9 (32.1)	41 (29.5)	0.780
Family history	8 (28.6)	27 (19.4)	0.278
UC duration (mo)	37 (7-81)	40 (4-90)	0.877
UC treatment
Mesalazine	22 (78.6)	115 (82.7)	0.601
Sulphasalazine	6 (21.4)	24 (17.3)
Anti-TNF	0 (0)	21 (15.1)	0.0281
Corticosteroids	5 (17.9)	60 (43.2)	0.0121
Hepatobiliary manifestations
Autoimmune hepatitis	1 (3.6)	0 (0)	NA
Fatty liver	18 (64.3)	10 (7.2)
Gall bladder stone	0 (0)	17 (12.2)
Liver abscess	0 (0)	1 (0.7)
Primary biliary cholangitis	1 (3.6)	1 (0.7)
PSC	0 (0)	104 (74.8)
Portal vein thrombosis	0 (0)	6 (4.3)
Reactive hepatitis	8 (28.6)	0 (0)
Type of PSC
Large duct PSC	0 (0)	83 (79.8)	NA
Small duct PSC	0 (0)	21 (20.2)
Family history of PSC	0 (0)	14 (10.1)	0.079
Hepatobiliary treatment	2 (7.1)	112 (80.6)	< 0.0011
High ALT	11 (39.3)	104 (74.8)	< 0.0011
High AST	16 (57.1)	105 (75.5)	0.0471
High Alkaline phosphatase	1 (3.6)	99 (71.2)	< 0.0011
High bilirubin	14 (50)	100 (71.9)	0.0231
Pain	20 (71.4)	90 (64.7)	0.496
Jaundice	13 (46.4)	94 (67.6)	0.0331
Pruritus	4 (14.3)	82 (59)	< 0.0011
Fever	1 (3.6)	34 (24.5)	0.0131
Fatty liver score	2 (1-3)	2 (2-3)	0.121

¹Significant.

Data were presented as mean ± SD, number (percentage), or median (min-max).

PSC: Primary sclerosing cholangitis; NA: Not applicable; Anti-TNF: Anti-tumour necrosis factor; UC: Ulcerative colitis; ALT: Alanine aminotransferase; AST: Aspartate transaminase.